Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients

por Abajo, A, Rodriguez, J, Bitarte, N, Zarate, R, Boni, V, Ponz, M, Chopitea, A, Bandres, E, Garcia-Foncillas, J
Publicado 2010

Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients

por Abajo, A, Boni, V, Lopez, I, Gonzalez-Huarriz, M, Bitarte, N, Rodriguez, J, Zarate, R, Bandres, E, Garcia-Foncillas, J
Publicado 2012

Antitumor activity of lurbinectedin in combination with oral capecitabine in patients with metastatic breast cancer

por Awada, A.H., Boni, V., Moreno, V., Aftimos, P., Kahatt, C., Luepke-Estefan, X.E., Siguero, M., Fernandez-Teruel, C., Cullell-Young, M., Tabernero, J.
Publicado 2022

Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study

por Boni, V., Pistilli, B., Braña, I., Shapiro, G.I., Trigo, J., Moreno, V., Castellano, D., Fernández, C., Kahatt, C., Alfaro, V., Siguero, M., Zeaiter, A., Longo, F., Zaman, K., Antón, A., Paredes, A., Huidobro, G., Subbiah, V.
Publicado 2022

A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma

por Piperno-Neumann, S., Carlino, M. S., Boni, V., Loirat, D., Speetjens, F. M., Park, J. J., Calvo, E., Carvajal, R. D., Nyakas, M., Gonzalez-Maffe, J., Zhu, X., Shirley, M. D., Ramkumar, T., Fessehatsion, A., Burks, H. E., Yerramilli-Rao, P., Kapiteijn, E.
Publicado 2023